Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 3/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 3/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 3/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 3/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509647 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9229193 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10236670 | 0.98 | PSEN1 (0.95) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL721328 | 0.98 | PSEN1 (0.95) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10236666 | 0.98 | PSEN1 (0.95) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10236610 | 0.96 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7914890 | 0.96 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL721969 | 0.96 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL235045 | 0.91 | CYP2C9 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7916744 | 0.91 | CYP2C9 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | PSEN1 5/4885PSEN2 10/4885APH1B 4/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.